Future Science Group celebrates 15 years of Regenerative Medicine, welcomes new Senior Editor

18 November 2020

Future Science Group (FSG; London, UK) is celebrating the 15-year anniversary of the journal Regenerative Medicine with the announcement of a new Senior Editor and a special feature on partner site RegMedNet highlighting the key advances made in the field over that time.

Since the first issue of Regenerative Medicine was published in January 2006, the field has exploded; the previous 15 years have seen the discovery of induced pluripotent stem cells (iPSCs) and their application in clinical trials, the first approved regenerative medicine therapy and the emerging ecosystem of clinics selling unproven and unapproved treatments.

In the last 15 years, Regenerative Medicine has grown to be one of the premier journals in this space, covering the latest translational research in regenerative medicine, with a special focus on the policy, ethics and social impact of this new technology. Key publications in recent years have covered the public perception of stem cells, challenges of dealing with ‘bad actor’ clinics and the changing nature of the stem cell ecosystem.

Coinciding with this anniversary year, FSG is delighted to announce that Professor André Terzic (Mayo Clinic, MN, USA) has joined Professor Chris Mason (AvroBio, MA, USA) as Senior Editor of the Regenerative Medicine. We feel Professor Terzic’s wealth of clinical experience will complement Professor Mason’s technological and industry expertise, and reflects the growth of the field from the bench to the bedside.

To mark 15 years of publications and to coincide with the completion of the 15th volume, the journal has partnered with RegMedNet for a special showcase, reviewing 15 years of regenerative advances and looking forward to what the next 15 years will bring. Featuring notable contributors from throughout the journal’s history, the showcase will provide insight into what has spurred the development of the field and what more can be done to ensure the patients who need it most are benefiting from this important work.

Adam Price-Evans, Managing Commissioning Editor of Regenerative Medicine, commented, “It has been a privilege to work on the journal for the last 4 years and I’ve been delighted to have this opportunity to look back on the fantastic work we’ve published thus far. Our team looks forward to working closely with Chris and André to champion regenerative medicine research and continue to develop the journal as it evolves the meet the needs of the field over the next 15 years.”

Visit ‘15 years of Regenerative Medicine’ on RegMedNet now>>

About Regenerative Medicine

Regenerative Medicine (IF: 2.598 (2019)) provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community. The journal focuses on the entire spectrum of approaches in regenerative medicine, including small molecule drugs, biologics, biomaterials, tissue engineering, and cell and gene therapies.

For additional information on the journal’s aims and scope, editorial board and the latest content, please visit the Future Medicine website: https://www.futuremedicine.com/journal/rme

Call for papers

The journal is currently inviting submissions of original research, review and perspective pieces, as well as shorter pieces such as editorials and organizational profiles. Submissions are being accepted via the journal’s online submission site. Alternatively, authors are invited to direct any article proposals or general queries to the Editorial Director, Laura Dormer, at [email protected].

About Future Science Group (FSG)

Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG’s portfolio consists of three publishing imprints, Future Science, Future Medicine and Newlands Press, as well as a content development imprint, PharmaPlatforms. In addition to a core business of subscription and open access journal publishing, FSG develops specialist knowledge networks and content hubs, such as RegMedNet, enabling professionals to easily connect and collaborate with their peers in niche scientific fields.

Don't forget to share this post!